Key facts
as of Oct 2026- Developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel and GPCR-driven diseases.
- Maxion Therapeutics is valued at approximately $110.6M as of Oct 2026 (last reported valuation).
- It has raised $105.1M; the latest was Later Stage VC ($89.2M) in Feb 2025.
- Notable investors include Innovate UK, General Catalyst, British Business Bank, BGF (Financial Services), Eli Lilly — 8 tracked in total.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$110.6M
Maxion Therapeutics's last reported valuation, Feb 2025. Nothing priced has surfaced since.
Free account
More of Maxion Therapeutics with a free account
- ·Watch Maxion Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for Maxion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About Maxion Therapeutics
Developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel and GPCR-driven diseases. The company combines mini-proteins found in venom and other sources called knottins into the antibody surface to create mixtures while creating the optimum drug-like properties of antibodies, enabling patients with chronic pain, autoimmune, and cardiovascular diseases to access safe, long-lasting, and selective treatments.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 50
- Website
- maxiontherapeutics.com/
- Ownership
- Privately Held (backing)